{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:44:06Z","timestamp":1770507846685,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.reuma.2013.04.012","type":"journal-article","created":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T16:52:40Z","timestamp":1383929560000},"page":"10-16","source":"Crossref","is-referenced-by-count":22,"title":["Reducci\u00f3n de dosis de terapias biol\u00f3gicas en enfermedades reum\u00e1ticas: an\u00e1lisis descriptivo de 153 pacientes en condiciones de pr\u00e1ctica cl\u00ednica"],"prefix":"10.1016","volume":"10","author":[{"given":"Jos\u00e9","family":"Inciarte-Mundo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Victoria","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violeta","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Ruiz-Esquide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Cabrera-Villalba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimon","family":"Sanmart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.reuma.2013.04.012_bib0005","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/annrheumdis-2011-201036","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases 2011","volume":"71","author":"Furst","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.04.012_bib0010","first-page":"CD007848","article-title":"Biologics for rheumatoid arthritis: An overview of Cochrane reviews","author":"Singh","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.reuma.2013.04.012_bib0015","first-page":"CD008794","article-title":"Adverse effects of biologics: A network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.reuma.2013.04.012_bib0020","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/ar1933","article-title":"Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register","volume":"8","author":"Listing","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reuma.2013.04.012_bib0025","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11926-012-0282-2","article-title":"Biologic therapies for spondyloarthritis: What is new?","volume":"14","author":"Baraliakos","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.reuma.2013.04.012_bib0030","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jbspin.2008.11.009","article-title":"Effect of discontinuing TNFalpha agonist therapy in patients with remission of rheumatoid arthritis","volume":"76","author":"Brocq","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.reuma.2013.04.012_bib0035","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reuma.2013.04.012_bib0040","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","article-title":"Extended dosing of etanercept 25mg can be effective in patients with ankylosing spondylitis: a retrospective analysis","volume":"29","author":"Lee","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reuma.2013.04.012_bib0045","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.04.012_bib0050","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/rheumatology\/keq060","article-title":"Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA","volume":"49","author":"Den Broeder","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.reuma.2013.04.012_bib0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2013.04.012_bib0060","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/rheumatology\/kes078","article-title":"The prevalence of clinical remission in RA patients treated with anti-TNF: Results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"51","author":"De Punder","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.reuma.2013.04.012_bib0065","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1136\/ard.2010.147751","article-title":"Discontinuation and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of BeSt study","volume":"70","author":"Van den Broek","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.04.012_bib0070","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/ard.2008.092254","article-title":"Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis","volume":"68","author":"Van der Kooij","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.04.012_bib0075","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.04.012_bib0080","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/ard.2009.117341","article-title":"Patients with RA in remission on TNF blockers: When and whom can TNF blocker therapy be stopped?","volume":"69","author":"Saleem","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2013.04.012_bib0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/annrheumdis-2012-eular.1831","article-title":"Reduced dose and frecuency of Anti-TNF therapy in rheumatic diseases [EULAR 2012. Abstract OP0148]","volume":"71","author":"Gibson","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"Suppl II","key":"10.1016\/j.reuma.2013.04.012_bib0090","first-page":"54","article-title":"Effects of low dose etanercept in mantaining DAS-remission previously achieved with standard-dose in patients with rheumatoid arthritis [EULAR 2012. Abstract OP0012]","volume":"66","author":"Botsios","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.04.012_bib0095","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","article-title":"Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease","volume":"30","author":"Comp\u00e1n-Navarro","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reuma.2013.04.012_bib0100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10067-007-0674-2","article-title":"Etanercept 25mg\/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients","volume":"27","author":"Lee","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"Supple3","key":"10.1016\/j.reuma.2013.04.012_bib0105","first-page":"133","article-title":"Dose reduction and\/or withdrawal of anti-TNF treatment in psoriatic arthritis [EULAR 2012 Abstract OP0161]","volume":"71","author":"L\u00f3pez-Vives","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.04.012_bib0110","first-page":"201","article-title":"Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: A long-term follow-up study","volume":"6","author":"Cantini","year":"2012","journal-title":"Biologics"},{"key":"10.1016\/j.reuma.2013.04.012_bib0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.reuma.2009.10.006","article-title":"Actualizaci\u00f3n del Documento de Consenso de la Sociedad Espa\u00f1ola de Reumatolog\u00eda sobre el uso de terapias biol\u00f3gicas en la artritis reumatoide","volume":"6","author":"Tornero-Molina","year":"2010","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reuma.2013.04.012_bib0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.reuma.2011.02.001","article-title":"Documento SER de consenso sobre el uso de teapia biol\u00f3gicas en artritis psori\u00e1sica","volume":"7","author":"F\u00e9rnandez","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reuma.2013.04.012_bib0125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.reuma.2010.12.002","article-title":"Documento SER de consenso sobre el uso de terapias biol\u00f3gicas en la espondilitis anquilosante y otras espondiloartritis, excepto la artritis psori\u00e1sica","volume":"7","author":"Juanola","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reuma.2013.04.012_bib0130","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/rheumatology\/41.6.638","article-title":"Dose titration using the disease activity score (DAS28) in rheumatoid arthritis patients treated with anti-TNF alpha","volume":"41","author":"Den Broeder","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.reuma.2013.04.012_bib0135","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/ard.2008.090860","article-title":"Increasing the infliximab dose in rheumatoid arthritis patients: A randomised, doble-blind study failed to confirm its efficacy","volume":"68","author":"Pavelka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.04.012_bib0140","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/ard.2007.083683","article-title":"Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study","volume":"67","author":"Van den Bemt","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.04.012_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","author":"Smolen","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.reuma.2013.04.012_bib0150","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jbspin.2006.03.010","article-title":"25mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy","volume":"74","author":"Berthelot","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.reuma.2013.04.012_bib0155","unstructured":"Evaluation of a standardized protocol for dose reduction in patients with Spondylarthropathies and clinical remission with anti-TNF therapy. ClinicalTrials.gov Identifier: NCT01604629"},{"key":"10.1016\/j.reuma.2013.04.012_bib0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcome with rituximab plus methotrexate in early rheumatoid arthritis: The IMAGE trial","volume":"70","author":"Tak","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2013.04.012_bib0165","first-page":"110","article-title":"Efficacy of different doses of rituximab for the treatment of RA: data from the CERERRA collaboration [EULAR 2012 Abstract OP0028]","volume":"71","author":"Chaztzidionysiou","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2013.04.012_bib0170","first-page":"121","volume":"71","author":"Dougados","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2013.04.012_bib0175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S0266462311000195","article-title":"Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment","volume":"27","author":"Kobelt","year":"2011","journal-title":"Int J Technol Assess Health Care"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X1300106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X1300106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T23:53:15Z","timestamp":1539215595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X1300106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1699258X1300106X"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2013.04.012","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}